Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer

• Published in: Journal of radiation research 2020-05, Vol.61 (3), p.494-498
• Main Authors: Tanaka, Hidekazu, Makita, Chiyoko, Manabe, Yuki, Kajima, Miki, Matsuyama, Katsuya, Matsuo, Masayuki
• Format: Article
• Language: English
• Subjects: Breast cancer; Cancer; Care and treatment; Chemotherapy; Denosumab; Metastasis; Radiation; Radiotherapy; Regular Paper; Zoledronic acid
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rraa020

Abstract Bone-modifying agents (BMAs) are frequently used for the treatment of bone metastases. Both BMA and radiation therapy (RT) are effective; however, there are few studies that have evaluated the efficacy of the combination treatment. We evaluated the effectiveness of RT + BMA in breast cancer-induced osteolytic bone metastasis as compared to BMA alone. A total of 43 lesions in 25 patients were evaluated. The median follow-up period was 18 (range, 2–90) months. None of the lesions was treated with chemotherapy or molecular targeted drugs during the follow-up period for evaluating the local response. Patients with complete or partial response were considered as responders, while those with stable or progressive disease were considered as non-responders. The rate of response with RT + BMA was significantly higher than that with BMA alone (P = 0.001). The cumulative incidence rate of response at 6 months was 54.4% in the RT + BMA group and 27.5% in the BMA alone group. The median time to response was 4 (range, 2–11) months in the RT + BMA group and 6 (range, 4–16) months in the BMA alone group. The overall survival rate in the responder group (83.1% at 1 year) was significantly higher than that in the non-responder group (37.5% at 1 year) (P = 0.029). In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis.